PBM
NKTR icon

Propel Bio Management’s Nektar Therapeutics NKTR Stock Holding History

Propel Bio Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-82,822
Closed -$3.5M – 39
2025
Q4 		$3.5M Buy
82,822
+33,822
+69% +$1.89M 2.99% 12
2025
Q3 		$2.79M Buy
+49,000
New +$1.62M 2.79% 12

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Propel Bio Management's NKTR Position: Q1 2026 in Review

Propel Bio Management sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 82,822 shares — an estimated $3.5M sold.

Propel Bio Management first reported a position in NKTR in Q3 2025 and held it in 2 quarters. The position peaked at $3.5M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Propel Bio Management reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Propel Bio Management sold 82,822 Nektar Therapeutics shares in Q1 2026, an estimated $3.5M.
  • Propel Bio Management first reported a position in Nektar Therapeutics in Q3 2025 and held it in 2 quarters.
  • Propel Bio Management's Nektar Therapeutics position peaked at $3.5M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.